483 related articles for article (PubMed ID: 20074149)
1. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
Sagi SV; Mittal S; Kasturi KS; Sood GK
J Gastroenterol Hepatol; 2010 May; 25(5):880-5. PubMed ID: 20074149
[TBL] [Abstract][Full Text] [Related]
2. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin and albumin combination treatment in hepatorenal syndrome.
Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
6. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study.
Alessandria C; Ottobrelli A; Debernardi-Venon W; Todros L; Cerenzia MT; Martini S; Balzola F; Morgando A; Rizzetto M; Marzano A
J Hepatol; 2007 Oct; 47(4):499-505. PubMed ID: 17560680
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
Testro AG; Wongseelashote S; Angus PW; Gow PJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1535-40. PubMed ID: 17784863
[TBL] [Abstract][Full Text] [Related]
10. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
Ghosh S; Choudhary NS; Sharma AK; Singh B; Kumar P; Agarwal R; Sharma N; Bhalla A; Chawla YK; Singh V
Liver Int; 2013 Sep; 33(8):1187-93. PubMed ID: 23601499
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin in hepatorenal syndrome.
Mazur JE; Cooper TB; Dasta JF
Ann Pharmacother; 2011 Mar; 45(3):380-7. PubMed ID: 21386023
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
Fabrizi F; Dixit V; Messa P; Martin P
Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
[TBL] [Abstract][Full Text] [Related]
14. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
Alessandria C; Debernardi-Venon W; Carello M; Ceretto S; Rizzetto M; Marzano A
Dig Liver Dis; 2009 Apr; 41(4):298-302. PubMed ID: 19158001
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
Saner F; Kavuk I; Lang H; Biglarnia R; Frühauf NR; Schäfers RF; Malagó M; Broelsch CE
Eur J Med Res; 2004 Feb; 9(2):78-82. PubMed ID: 15090293
[TBL] [Abstract][Full Text] [Related]
17. Review article: pharmacological treatment of hepatorenal syndrome.
Ginès P; Torre A; Terra C; Guevara M
Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
[TBL] [Abstract][Full Text] [Related]
18. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin. Type I hepatorenal syndrome: an extra window of time before liver transplantation.
Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17171813
[TBL] [Abstract][Full Text] [Related]
20. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]